Human Chorionic Gonadotropin Market By Treatment (Female Infertility Treatment, Oligospermia Treatment, Cryptorchidism Treatment), By Technology (Natural Source Extraction, Recombinant Dna Technology) - Growth, Share, Opportunities & Competitive Analysis, 2016 - 2022
Fertility patterns worldwide have changed dramatically and a rise in the infertility rates have been observed since the last two decades. Even though newer assisted techniques such as in-vitro fertilization have been well developed, still fertility drugs are the first choice for treatment of infertility issues. Even in the fertility drugs category, hormonal products are preferred the most. Since the human body is governed by hormones, infertility is considered to be caused due to the abnormal play of the hormones.
This report studies the global human chorionic gonadotropin (HCG) market based on use of human chorionic gonadotropin in various treatments and production technologies. HCG is widely used for female infertility treatment, oligospermia, and cryptorchidism treatments. Based on manufacturing technologies the HCG market is categorized into natural source extraction and recombinant DNA technology. This report studies these segments in terms of their historical and future market size and forecast for the period 2014-2022. Respective compounded annual growth rates (CAGR %) for these segments for the period 2016-2022 are also presented in this study.
Geographically, the global human chorionic gonadotropin market is studied for the following regional markets:
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Rest of Asia-Pacific
- Middle East and Africa
- Latin America
The market size and forecast for the period 2014-2022 along with the CAGRs for the period 2016-2022 are also provided in this report.
Qualitative information such as drivers, restraints and future opportunities for the global hospital-acquired disease testing market are included in this report. Competition assessment tools such as competition analysis and attractive investment proposition are presented in this study for scrutinizing competition of the global human chorionic gonadotropin market. This study concludes with the company profiles section that highlights information about the key companies engaged in development, manufacture and provision of human chorionic gonadotropin products.
Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions
Chapter 2 Executive Summary
2.1 Global Human Chorionic Gonadotropin Market, by Therapeutic Area, 2015 (USD Mn)
2.2 Global Human Chorionic Gonadotropin Market, by Technology, 2015 (USD Mn)
2.3 Global Human Chorionic Gonadotropin Market, by Therapeutic Area Market, by Geography, 2015 (Value %)
Chapter 3 Global Hematopoietic Stem Cells Market Overview
3.1 Overview
3.2 Market Drivers
3.2.1 High Infertility Prevalence Worldwide
3.3 Market Restraints
3.3.1 Availability of Substitutes
3.4 Market Opportunities
3.4.1 Demand for Recombinant HCG
3.5 Attractive Investment Proposition
3.6 Market Competition Assessment: Human Chorionic Gonadotropin Market, by Key Players
Chapter 4 Global Human Chorionic Gonadotropin Market Analysis, By Treatment
4.1 Overview
4.2 Female Infertility Treatment
4.3 Oligospermia Treatment
4.4 Cryptorchidism Treatment
4.5 Others
Chapter 5 Global Human Chorionic Gonadotropin Market Analysis, By Technology
5.1 Overview
5.2 Natural Source Extraction
5.3 Recombinant DNA Technology
Chapter 6 Global Human Chorionic Gonadotropin Market, By Geography
6.1 Preface
6.2 North America
6.3 Europe
6.4 Asia-Pacific
6.5 Latin America
6.6 Middle East and Africa
Chapter 7 Company Profiles
7.1 Ferring B.V.
7.1.1 Ferring B.V.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.2 Bristol-Myers Squibb Company
7.2.1 Bristol-Myers Squibb Company: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.3 EMD Serono, Inc.
7.3.1 EMD Serono, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.4 Fresenius Kabi USA, LLC
7.4.1 Fresenius Kabi USA, LLC: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.5 Merck & Co., Inc.
7.5.1 Merck & Co., Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 1 Therapeutics Category
TABLE 2 Market Competition Assessment: Human Chorionic Gonadotropin Products, by Key Players
TABLE 3 Global Human Chorionic Gonadotropin Market, by Treatment, 2014-2022 (USD Mn)
TABLE 4 Global Human Chorionic Gonadotropin Market, by Technology, 2014-2022 (USD Mn)
TABLE 5 Global Human Chorionic Gonadotropin Market, by Geography, 2016 – 2022 (USD Mn)
TABLE 6 Ferring B.V.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 7 Bristol-Myers Squibb Company: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 8 EMD Serono, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 9 Fresenius Kabi USA, LLC: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 10 Merck & Co., Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
FIG. 1 Human Chorionic Gonadotropin Market: Research Methodology
FIG. 2 Global Human Chorionic Gonadotropin Market, by Therapeutic Area, 2015 (USD Mn)
FIG. 3 Global Human Chorionic Gonadotropin Market, by Technology, 2015 v/s 2022 (Value %)
FIG. 4 Global Human Chorionic Gonadotropin Market, by Geography, 2015 (Value %)
FIG. 5 Attractive Investment Proposition, by Geography, 2015
FIG. 6 HCG Market in Female Infertility Treatment, 2014 – 2022 (USD Mn)
FIG. 7 HCG Market in Oligospermia Treatment, 2014 – 2022 (USD Mn)
FIG. 8 HCG Market in Cryptorchidism Treatment, 2014 – 2022 (USD Mn)
FIG. 9 HCG Market in Other Treatments, 2014 – 2022 (USD Mn)
FIG. 10 HCG from Natural Source Extraction Market, 2014 – 2022 (USD Mn)
FIG. 11 HCG from Recombinant DNA Technology Market, 2014 – 2022 (USD Mn)
FIG. 12 North America Human Chorionic Gonadotropin Market, By Country, 2013 – 2022 (USD Mn)
FIG. 13 Europe Hematopoietic Stem Cell Transplant Market , 2013 – 2022 (USD Mn)
FIG. 14 Asia-Pacific Human Chorionic Gonadotropin Market , 2013 – 2022 (USD Mn)
FIG. 15 Latin America Human Chorionic Gonadotropin Market, 2016 – 2022 (USD Mn)
FIG. 16 Middle East and Africa Human Chorionic Gonadotropin Market, 2016 – 2022 (USD Mn)
Choose License
Contact Information
: sales@briskinsights.com
: +448081890034 (UK)